Proprietary whole blood rapid manufacturing process for CAR T-cell therapies, designed to eliminate apheresis starting material and reduce manufacturing turnaround time; focus on autologous CD19 CAR T for autoimmune diseases

Targets: CD19

Biotech Distilled coverage (4)

2026-06-03 UPDATE: Kyverna Therapeutics (KYTX) - The RA Receipts Land, the Stock Doesn’t Care
2026-05-12 UPDATE: Kyverna Therapeutics (KYTX) - The BLA Clock Starts 🔒 Paid
2026-04-27 UPDATE: Kyverna Therapeutics (KYTX) - The SPS Receipts Land, And They’re Better Than the Topline 🔒 Paid
2026-04-22 Kyverna Therapeutics (KYTX) - Scientific Deep Dive for Miv-Cel and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.